From Biodiversity to Billion-Dollar Products: Can Indonesia Turn Biology Into Industry?

Our earlier work established that Indonesia's biodiversity is real and vast, and that the broader commercialization gap sits between discovery and industry rather than at discovery itself. This article tests both claims against Indonesia's single most distinctive scientific asset — and finds the same pattern, with sharper numbers.

The Resource Was Never the Question

Indonesia's biodiversity credentials are not in dispute. It is one of only 17 countries classified as "megadiverse," together holding roughly 70% of all known species on Earth. Indonesia's own submission to the Convention on Biological Diversity puts its plant species count at approximately 31,750 — a figure BPOM's leadership has independently cited as "more than 30,000," or roughly 15.5% of the world's flowering-plant species concentrated in 1.3% of the planet's land area. Its Coral Triangle is widely regarded as the highest-biodiversity marine ecosystem on Earth.

This article does not repeat that case at length. The question here is different: given that the biological resource is real, does it convert into industry? We have argued that Indonesia's broader innovation system has a commercialization problem, not a science problem. This article tests that claim against biodiversity specifically — and finds a pattern even more sharply quantified than the patent-licensing data.

Investor Snapshot

Figures drawn from Indonesia's CBD Sixth National Report, BPOM official statements, and the peer-reviewed literature cited at the end of this article.

Indonesia Already Leads Regional Discovery

Far from unexplored, Indonesian biodiversity is the most heavily studied in Southeast Asia. A March 2026 peer-reviewed review in Molecules, co-authored by an IPB University researcher, analyzed 645 publications on new marine natural products from Southeast Asia between 2003 and 2022. Indonesia contributed 29.4% of them — the largest single-country share, ahead of Vietnam and Thailand.

The same review found Indonesia holds 731 described sponge species, the highest count in Southeast Asia, and that Indonesian-sourced sponge samples account for 48.2% of all Porifera-related marine natural product publications from the region. A separate systematic review in Natural Products and Bioprospecting found nearly 1,000 distinct chemical compounds have been extracted and identified from Indonesian marine organisms since 1988.

That settles the question this article opened with: Indonesian biodiversity is already one of the most actively researched biological resource bases in the tropical world. The relevant question for an investor is not whether Indonesian biology is being studied — it clearly is — but what happens to the value that research creates.

Discovery Without Ownership: The Value-Capture Gap

The same March 2026 review cites a 50-year capacity-building analysis (Leal et al.) that goes to the heart of this article's argument: Indonesian-affiliated researchers appear as authors on only 50% of publications describing organisms collected from Indonesian waters, and hold a lead-author position — first or last author, the roles that typically carry the most scientific and commercial credit — in just 20% of them. Thailand, by contrast, co-authors 80% of its own country's marine natural product publications and leads 85% of them.

Both countries supply comparable biological material to international research. What differs is who leads the resulting science, and by extension who is positioned to hold the resulting IP, follow-on funding relationships, and licensing rights. Indonesia's marine biodiversity is generating a large and growing body of publishable, patentable discovery — but a large share of the credit, and likely a large share of the resulting IP position, is not staying with Indonesian institutions.

The genus Acanthostrongylophora, a sponge collected primarily from Manado Bay and North Sulawesi, illustrates the pattern concretely. More than two decades of research by mixed Indonesian and international teams has produced over 200 manzamine-type alkaloid compounds — with documented antimalarial, antitubercular, antiviral and anticancer activity, including specific compounds active against drug-resistant tuberculosis and HIV-1 in laboratory testing. It is a genuine Indonesian biodiversity success in scientific terms, and a live test case for the value-capture question, since the compound family's commercial and IP trajectory has involved international pharmaceutical chemistry groups as much as Indonesian ones.

The Legal Foundation Exists; Implementation Doesn't

Indonesia ratified the Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from Their Utilization in 2013, through Law No. 11/2013, following its 2011 signature. Ratification gives Indonesia a sovereign legal claim over its genetic resources and traditional knowledge, and a stated policy objective — explicit in the law's own preamble — of preventing biopiracy: the uncompensated extraction and commercialization of Indonesian biological material and traditional knowledge by foreign parties.

A 2025 legal analysis published in the International Journal of Science and Research Archive found that, despite ratification, Indonesia still lacks a unified, specific implementing law on genetic-resource access and benefit-sharing. Existing legal tools — patent law, communal intellectual property regulation, and conservation legislation — were found to inadequately protect traditional knowledge and collective community rights, and fragmented institutional oversight and the absence of a unified genetic-resource database were identified as continuing vulnerabilities to unauthorized foreign exploitation.

This bears directly on the value-capture gap described above. A ratified treaty establishes Indonesia's right to require prior informed consent and benefit-sharing agreements before its genetic resources are commercially exploited. Whether that right is being systematically exercised, tracked, and enforced in practice — as opposed to existing on paper — remains, per the available legal literature, an unresolved question.

From Jamu to Fitofarmaka: A Bottleneck With Exact Numbers

Nowhere in our research is the commercialization gap more precisely quantified than in Indonesia's own traditional-medicine classification system. Indonesia regulates natural medicine in three tiers of increasing scientific rigor: jamu, based on empirical and historical use with no formal preclinical or clinical testing requirement; Obat Herbal Terstandar (OHT, standardized herbal medicine), which requires preclinical proof and standardized raw materials; and fitofarmaka (phytopharmaceutical), which requires full preclinical and human clinical trial evidence.

According to BPOM Head dr. Taruna Ikrar, M.Biomed, Ph.D.Med.Sc., speaking at Universitas Andalas in July 2026, Indonesia has approximately 20,000 registered jamu distribution permits. Of those, only 71 products have advanced to OHT status, and only 20 products across the entire system have reached fitofarmaka status — the tier with genuine clinical evidence behind it. BPOM figures from the preceding two years (77–81 OHT products and 20–22 fitofarmaka products, reported between September 2024 and March 2025) confirm this is a stable, structural bottleneck rather than a one-time anomaly.

dr. Taruna Ikrar also put a number on what the bottleneck costs. Based on Indonesia's plant-based medicine raw material base — he cited approximately 31,000 of the roughly 40,000 plant species used in medicine worldwide as originating in Indonesia — his team calculated the addressable market potential for authentic Indonesian medicine at Rp350 trillion. The realized value in 2025, by his own account, was approximately Rp2 trillion: under 1% of the estimated potential.

The Biodiversity-to-Product Pipeline

Sources: CBD Sixth National Report; MDPI Molecules (2026); Natural Products and Bioprospecting (2023); BPOM public statements (2024–2026); Law No. 11/2013; International Journal of Science and Research Archive (2025).

What This Means for Investors

Indonesia's biological resource base and its research output on that base are both genuinely world-leading — this is not a market where the underlying science needs to be built from nothing. Because the constraint is demonstrably not discovery, an investor entering now is not racing to find undiscovered biology, but to build the standardization, validation and IP-ownership infrastructure that converts already-documented discoveries into products:

• Growth driver: BPOM's own Rp350 trillion potential-market estimate, against roughly Rp2 trillion realized, defines a specific, government-quantified gap in traditional medicine alone — before cosmeceuticals, nutraceuticals and marine-derived pharmaceuticals are counted.
• Barrier: the value-capture gap in marine natural products research (20% Indonesian lead-authorship versus 85% for Thailand) and the fragmented ABS implementation described in the legal literature both point to the same issue: Indonesian institutions are not yet structurally positioned to lead or fully benefit from research on Indonesian biological material.
• Investment gap: standardization and clinical-validation capacity for traditional medicine, and research partnership structures that build Indonesian lead-authorship and IP ownership rather than simply accessing Indonesian biological material.
• Entry models: joint research agreements structured around co-lead-authorship and shared IP from the outset; direct investment in preclinical and clinical validation of high-potential jamu formulations; proactively negotiated benefit-sharing agreements; and ingredient-standardization partnerships connecting to the cosmeceutical and nutraceutical gaps identified in our sector map.

Converting Discovery Into Ownership

The pattern is consistent: Indonesia is not short on biological resources, and it is not short on research about those resources. What is missing, at every stage from marine natural products to traditional medicine, is the infrastructure that lets Indonesian institutions lead that research, standardize its outputs, and retain a proportionate share of the resulting commercial and intellectual property value.

SciencePreneur's role in this specific gap is to help structure exactly that kind of partnership — connecting foreign investors and research organizations with Indonesian universities and research institutes in ways that build local research leadership and IP position from the outset, rather than defaulting to a pure biological-access arrangement. That includes supporting the standardization and validation work that moves a jamu formulation toward OHT or fitofarmaka status, and structuring benefit-sharing terms clearly enough to withstand the regulatory ambiguity documented above.

Where This Leaves the Investor

This article has made a narrower, more falsifiable claim than "Indonesia has great biodiversity." It has argued, with Indonesia's own regulator's numbers, that the gap between Indonesia's biological resource base and its commercial output is real, large, and precisely measurable — and that it sits specifically at standardization, validation, research leadership and IP ownership, not at the existence or discovery of the underlying biology. The opportunity is not "access to Indonesian biodiversity" in the abstract — that access already exists and is already being exercised, heavily, by researchers worldwide. The opportunity is in the infrastructure and partnership structures that let discovery convert into Indonesian-owned, standardized, investable products.